Carmell Therapeutics (CTCX) Cash per Single Share

Carmell Corporation - graphic logo of issuer CTCX

Carmell Corporation focuses on regenerative medicine, facing a lack of profitability and a dependence on patents. The firm's environmental footprint is minimal and limited to chemical disposal. Quarterly cash per share dynamics demonstrate that the current status equals 0.07. However, a lack of commercialization experience and the risks of bioplaster test failures leave the capital vulnerable to the need for external financing.

Cash per Share: Carmell (CTCX) for 02/21/2024 - 03/10/2025

Analytical breakdowns for Carmell Corporation

- market value and analyst target forecast:
- cash availability and cash flow indicators:
Summary company analysis:CTCX (Carmell Therapeutics)
Flagship merchandise of Carmell

Cash per share determines the volume of liquid capital attributable to a single security. An increase in this metric indicates financial stability and the company's ability to fund growth without external borrowing. By analyzing cash per share trends, an investor distinguishes real resource accumulation from speculative fluctuations. For Carmell Corporation (CTCX), this reserve is critical when implementing robotic bioscreening systems. The automation of plasma matrix production requires significant capital expenditures in high-tech equipment.